Full-Time

Senior Staff Supplier Relationship

Posted on 11/23/2025

Illumina

Illumina

5,001-10,000 employees

Accelerates genomics startups through funding

Compensation Overview

$126.8k - $190.2k/yr

+ Bonus + Commission

No H1B Sponsorship

Madison, WI, USA + 2 more

More locations: Hayward, CA, USA | San Diego, CA, USA

In Person

Category
Operations & Logistics (2)
,
Requirements
  • Requires a minimum of 12 years of related experience with a Bachelor’s degree; or 10 years and a Master’s degree, or a PhD with 7 years of experience; or equivalent experience
  • Ability to travel up to 25% of the time; both domestic and international
  • Proficient in use of Microsoft Office (Project, Word, Excel, Outlook, PowerPoint)
Responsibilities
  • Lead sustaining sourcing activities for on-market products and provide functional leadership and direction for sustaining products.
  • Lead the sustaining roadmap creation and implementation of category strategies for assigned categories. Evaluates competitive alternatives. Obtains approval for strategies from senior executive stakeholders.
  • Lead assurance of supply escalations and supplier risk mitigation management with cross function stakeholders/team.
  • Lead strategic/promote supplier quarterly business reviews resulting in supplier performance improvements through collaboration with R&D, Operations, and Quality. Proactively works with business partners and sponsors to align key messages with Suppliers.
  • Collaborate with suppliers to develop capabilities, supply continuity, and capacity. Full understanding of Supplier’s business continuity plans, technical risks, financial risks, etc. that may impact Illumina’s business.
  • Lead and contribute global product/material cost reduction initiatives via value engineering, cost negotiation and resourcing efforts.
  • Drive alternative supplier/part qualification with cross function stakeholders/team.
  • Advocate for compliance with Illumina policies and procedures.
  • Ensure system data is set up correctly for suppliers under areas of responsibility to facilitate efficient ‘Procure to Pay’ processes.
  • Lead and manage continuous improvement initiatives across a broad business area.
  • Partner with executive stakeholders to contribute to the development of company objectives and principals.
  • Negotiate various types of agreements (i.e., supply, scheduling, consignment, statement of work, CDAs, etc.) achieving favorable terms that mitigate business risks and protect Illumina’s IP while reducing product cost and inventory levels.
  • Establishes and leads Governance processes with Suppliers to reduce business risk and support manufacturing site escalations. Ensures appropriate engagement with Quality and Regulatory when implementing supplier / specification change programs.
Desired Qualifications
  • Strategic thinker; anticipates and develops business and regulatory opportunities and priorities for future action while also executing on concrete business objectives. Links plans to organization strategies.
  • Broad expertise that can be applied to a range of business areas. Customer focused, able to collaborate and influence others to drive actions to meet business needs while maintaining a positive, professional outlook. Comfortable challenging status-quo in order to improve processes.
  • Flair for creating effective, cross functional networks involving coordination among groups.
  • Strong analytical skills that allow the successful candidate to extract core data from a variety of sources, draw conclusions and insights, and translate those insights into actions.
  • Ability to deal effectively with pressure, multiple tasks, deadlines, and rapidly changing priorities.
  • Excellent verbal and written communication skills with requisite interpersonal skills to partner, collaborate and build relationships with business partners, suppliers, and regional teams.
  • Facilitates meetings effectively ensuring that communication styles are appropriate given the differing needs of culturally diverse, global teams.
  • Expert in the use of enabling systems (Ariba, SAP, Quickbase) to track progress, identify gaps, and develop plans to address.
  • Solid understanding of industry financial / category trends and leverage these to improve Illumina’s supply chain.
  • Aptitude to understand suppliers key cost drivers, interpret basic financial and balance sheet reporting, and provide recommendations.
  • Strong negotiator; ability to negotiate the best deal for ILMN and influence upward.
  • International sourcing and supplier management experience; preferably in area of responsibility.
  • Ability to travel up to 25% of the time; both domestic and international.
  • Proficient in use of Microsoft Office (Project, Word, Excel, Outlook, PowerPoint).

Illumina Accelerator helps create and grow genomics startups by partnering with venture investors and entrepreneurs as part of Illumina for Startups. It runs as a company-creation engine co-located with Illumina’s R&D sites in the San Francisco Bay Area and Cambridge, UK, offering mentorship, resources, and access to Illumina’s technology and networks. Its edge comes from Illumina’s sequencing tech, R&D resources, and a global network, plus a track record of 68 funded startups that have raised over $1 billion. The goal is to support ideas turning into market-ready genomics products and companies.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

San Diego, California

Founded

1998

Simplify Jobs

Simplify's Take

What believers are saying

  • Q1 2026 revenue reached $1.09 billion, up 4.8% year over year.
  • The board approved an additional $1.5 billion share repurchase authorization in April 2026.
  • StrataMap, MRD, and fireflyGO deepen Illumina’s oncology and spatial research portfolio.

What critics are saying

  • Alternative long-read and non-Illumina platforms threaten short-read sequencing share and consumables pull-through.
  • StrataMap depends on existing instrument customers upgrading, delaying commercialization if adoption lags.
  • Large collaborations like the Billion Cell Atlas depend on partner commitment and data utility.

What makes Illumina unique

  • Illumina combines sequencing, arrays, DRAGEN analytics, and Connected Insights workflows.
  • Its installed base supports launch adoption across NovaSeq, NextSeq, and MiSeq systems.
  • The company is expanding into spatial transcriptomics, oncology, and single-cell perturbation datasets.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Illumina who can refer or advise you

Benefits

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

-2%
Oregon Capital Insider
May 21st, 2026
David P. King elected to Illumina's Board of Directors.

David P. King elected to Illumina's Board of Directors. PR Newswire Today at 1:15pm PDT Former Labcorp Chairman and CEO brings deep healthcare, diagnostics, and clinical expertise to Illumina's Board SAN DIEGO, May 21, 2026 /PRNewswire/ - Illumina, Inc. (NASDAQ: ILMN) today confirmed the election of David P. King to its Board of Directors, effective immediately following the company's annual meeting of shareholders. Mr. King's election marks an important addition to Illumina's Board as the company accelerates its clinical strategy to integrate genomics more broadly into the standard of care. "We are delighted to welcome David to the Illumina Board," said Jacob Thaysen, chief executive officer of Illumina. "David brings deep regulatory knowledge, broad industry credibility, and the respect earned over decades at the forefront of healthcare and life sciences. Under his leadership at Labcorp, the company tripled in size through organic growth and strategic acquisitions. His perspective across diagnostics, healthcare delivery, and board governance will strengthen our ability to deliver long-term impact for patients, customers, and shareholders." Mr. King is the former Executive Chairman and Chief Executive Officer of Labcorp. Under his leadership, Labcorp entered the Fortune 500, and was recognized by Fortune as one of the World's Most Admired Companies. Mr. King joins the Board following the retirement of Frances Arnold, PhD, Robert S. Epstein, MD, and Gary S. Guthart, PhD, each of whom concluded distinguished tenures on the Board at the company's annual meeting. About David P. King David P. King was elected to Illumina's Board of Directors in 2026. Mr. King has extensive experience in the healthcare and life sciences sectors in executive and non-executive roles, including leading complex businesses at scale, driving operational excellence and commercial initiatives, and executing transformational change through M&A and organic growth. Mr. King served as Chair and Chief Executive Officer as well as Executive Chairman of Laboratory Corporation of America Holdings (Labcorp) from 2007 to 2019. He provides strategic advisory services across the healthcare ecosystem through KingMan LLC. Mr. King also serves as Chair of Privia Health Group, Inc., as a director of Smith & Nephew, and has served in board leadership roles across a range of healthcare companies, including as Chair of ZimVie (2022-2025) and as Non-Executive Chair of PathGroup, LGC Limited, and AmSurg. Earlier in his career, Mr. King was a partner at Hogan & Hartson LLP (now Hogan Lovells) and served as an Assistant U.S. Attorney for the District of Maryland. Mr. King received a B.A. from Princeton University and a J.D. from the University of Pennsylvania Law School. About Illumina Illumina is improving human health by unlocking the power of the genome. Its focus on innovation has established Oregon Capital Insider as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Its products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with Oregon Capital Insider on X, Facebook, LinkedIn, Instagram, TikTok, and YouTube. Investors: Illumina Investor Relations 858-291-6421 [email protected] SOURCE Illumina, Inc. This is a paid placement. For further inquiries, please contact PR Newswire directly.

Mitalab Co., Ltd.
May 14th, 2026
Mitalab officially becomes A comprehensive distribution partner of Illumina.

Mitalab officially becomes A comprehensive distribution partner of Illumina. Dear Valued Partners and Customers, Mitalab is honored to announce a significant strategic milestone in its collaboration journey. Effective from May 13, 2026, Mitalab has officially become the comprehensive distributor of both Illumina's "IVD Diagnostics" and "RUO Research" product portfolios. Illumina is globally recognized as a leading innovator in genomic sequencing and biotechnology. Becoming an authorized distributor for both the IVD and RUO product lines not only marks a major advancement in the partnership between Mitalab and Illumina, but also demonstrates Mitalab's professional expertise, operational capability, and strong reputation in the healthcare and life sciences sector. Mitalab is committed to delivering a comprehensive Next-Generation Sequencing (NGS) ecosystem that simultaneously supports clinical applications, enhances diagnostic and treatment efficiency, and advances in-depth scientific research. As modern medicine and genomic technologies continue to play an increasingly vital role in healthcare, Mitalab's access to Illumina's advanced platforms will create new opportunities to improve the quality of medical diagnosis, laboratory services, and scientific research for hospitals, laboratories, research institutes, and the scientific community across Vietnam. This milestone is not only a source of pride for Mitalab, but also a strong motivation for Mitalabvn to continuously update and deliver cutting-edge medical technologies, contributing to the advancement of diagnostics, scientific innovation, and community healthcare. Once again, congratulations on this remarkable and meaningful partnership milestone.

PR Newswire
Apr 14th, 2026
Illumina and D3b unite 100,000 pediatric genomes to accelerate rare disease and cancer research

Illumina and the Center for Data-Driven Discovery in Biomedicine have announced a data partnership to advance paediatric cancer and rare disease research. D3b is analysing 100,000 whole genomes from paediatric patients using Illumina software solutions, creating one of the largest unified genomic datasets ever assembled. The resulting insights will be made available through the Gabriella Miller Kids First Data Resource Centre, enabling researchers and clinicians to uncover biological origins of rare diseases and cancers. The dataset includes whole genomes from patients with rare congenital conditions and cancers, analysed using DRAGEN v4.4 and Illumina Connected Analytics. Additionally, Illumina is supporting D3b in the Pediatric Care eXpansion programme, which aims to reduce patient care journeys from months to weeks through a national data exchange spanning over 200 US paediatric institutions.

Food Safety Magazine
Apr 13th, 2026
USDA-FSIS updates WGS laboratory method.

USDA-FSIS updates WGS laboratory method. April 13, 2026 The U.S. Department of Agriculture's Food Safety and Inspection Service (USDA-FSIS) has updated its whole genome sequencing (WGS) laboratory method to incorporate the Illumina MiSeq i100 sequencing platform. MiSeq i100 represents the next generation of MiSeq sequencing instrumentation featuring integrated sequencing chemistry and substantially reduced runtimes. FSIS reports that this modernization enhances its laboratory system's ability to generate consistent, high-quality genomic data with increased laboratory sample throughput. The updated Microbiology Laboratory Guidebook (MLG) chapter 42, "Whole Genome Sequencing of Bacterial Isolates," now includes protocols for using both the Illumina MiSeq and MiSeq i100 platforms. FSIS will begin integrating the MiSeq i100 platform starting in May 2026, through the remainder of the fiscal year as existing laboratory supplies are exhausted and additional i100 units come online across FSIS laboratories. The current MiSeq instrumentation remains fully valid and equivalent for WGS analyses and will continue to be used where appropriate. WGS determines the full DNA sequence of an organism in a single laboratory protocol, and FSIS performs WGS on every bacterial isolate obtained from regulated food product and environmental samples. This publicly available data supports foodborne pathogen monitoring, food safety research, and other regulatory applications. FSIS notes that the inclusion of a specific commercial product in the MLG should not be considered an endorsement by the agency. Looking for quick answers on food safety topics? Try Ask FSM, our new smart AI search tool. Ask FSM SPONSORED BY Hi there. I'm Ask FSM. You can ask me anything about science-based solutions f The Food Safety Magazine editorial team comprises Bailee Henderson, Digital Editor | and Adrienne Blume, M.A., Editorial Director. JOIN TODAY to unlock your recommendations. Already have an account? Sign In

Yahoo Finance
Apr 9th, 2026
Illumina shares up 31.7% since October despite declining organic revenue and mediocre ROIC

Illumina has gained 31.7% since October 2025, reaching $126.99 per share, outpacing the S&P 500's 1.8% decline. Despite this performance, analysts cite three concerns about the genomics company. Illumina's organic revenue has declined an average of 1.1% year-on-year over the past two years, suggesting weakness in its core business. The company's earnings per share grew just 1.5% annually over five years, below its 6% revenue growth, indicating decreasing profitability. Additionally, its five-year average return on invested capital of 0.3% falls below typical healthcare sector costs. Trading at 24.7× forward price-to-earnings, the stock may present excessive downside risk despite recent gains, according to the analysis.

INACTIVE